New Collaboration to Increase Payer Reimbursements and Patient Access LITTLETON, Colo., Dec. 15, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today announced the creation of a new strategic collaboration with Nexus Dental Systems (“Nexus”), which Vivos expects to generate new revenues starting immediately. Vivos and Nexus believe their alliance…

Welcome to the Wild World of Class Action Lawsuits What’s the Buzz About? Hey there, investor! If you’ve got some skin in the game with Generac Holdings, Inc. (NYSE: GNRC), Veru Inc. (NASDAQ: VERU), or F45 Training Holdings, Inc. (NYSE: FXLV), you might want to perk up those ears. Bragar Eagel & Squire, P.C., a…

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-… Keros Therapeutics Hosts Conference Call and Webcast Keros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET. The event will provide an opportunity for investors, analysts, and the general public to learn more about the latest clinical…

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax Antileukemic Activity Demonstrated ALX Oncology recently announced the initial data from the ASPEN-05 study, showcasing promising antileukemic activity in patients with both relapsed/refractory and newly diagnosed Acute Myeloid Leukemia (AML). No Observations of Cytopenias or Maximum Tolerated Dose The…

The Impact of Voyager Digital Holdings Investor Losses Introduction Recently, Rosen Law Firm has issued a reminder to purchasers of Voyager Earn Accounts and VGX tokens about potential losses incurred between January 1, 2020 and November 9, 2022. This news has caused a stir among investors and raised questions about the security and reliability of…

Agios Pharmaceuticals Presents Updated PYRUKYND® Data Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Agios Pharmaceuticals, Inc. is currently conducting Phase 3 ENERGIZE and ENERGIZE-T studies to evaluate the effectiveness of PYRUKYND® in adults with non-transfusion-dependent and transfusion-dependent α- or β-Thalassemia, respectively. This innovative drug has shown promise in improving outcomes for patients with these…

Welcome to Kaplan Fox & Kilsheimer LLP An Investigation into Silvergate Capital Corp Dec 09, 2022 Kaplan Fox & Kilsheimer LLP, a renowned law firm, is currently conducting an investigation on behalf of investors of Silvergate Capital Corp. The firm is looking into claims regarding Silvergate, listed on the New York Stock Exchange under the…

The Growing Demand for Electric Vehicles and Technology New York, US, Dec. 09, 2022 (GLOBE NEWSWIRE) — According to a comprehensive research report by Market Research Future (MRFR), “Vehicle Electrification Market Research Report: Information by Product, Sales Channel, Voltage, Region, and Vehicle– Forecast till 2030”, the global market for vehicle electrification is predicted to bolster…